World's Best Scientists 2026 revealed!
Jeffrey L. Lennox

Jeffrey L. Lennox

D-Index & Metrics

Discipline name D-Index World Ranking Current World Ranking National Ranking Current National Ranking Publications Citations
Microbiology 44 5107 4713 1965 1763 111 9167

Jeffrey L. Lennox publications per year

The chart shows the history of publications by Jeffrey L. Lennox between 1973 and 2024, highlighting the no. of papers published in each year and offering an overview of the publication velocity of this scholar. Jeffrey L. Lennox published across 52 years, from 1973 to 2024, averaging 2.3 papers a year. Output peaked at 10 publications in 2008. 2 of the 118 publications appeared in the last two years.

No. of publications
2 4 6 8 10
Bar chart. Horizontal axis: year, 1973 to 2024. Vertical axis: number of publications, 0 to 10. Peak 10 publications in 2008. 1973: 1 publication 1974: 0 publications 1975: 0 publications 1976: 0 publications 1977: 0 publications 1978: 0 publications 1979: 0 publications 1980: 0 publications 1981: 0 publications 1982: 0 publications 1983: 0 publications 1984: 0 publications 1985: 0 publications 1986: 0 publications 1987: 1 publication 1988: 0 publications 1989: 1 publication 1990: 0 publications 1991: 1 publication 1992: 0 publications 1993: 0 publications 1994: 0 publications 1995: 0 publications 1996: 1 publication 1997: 0 publications 1998: 3 publications 1999: 0 publications 2000: 4 publications 2001: 5 publications 2002: 5 publications 2003: 6 publications 2004: 1 publication 2005: 4 publications 2006: 2 publications 2007: 4 publications 2008: 10 publications 2009: 5 publications 2010: 6 publications 2011: 5 publications 2012: 8 publications 2013: 4 publications 2014: 10 publications 2015: 4 publications 2016: 4 publications 2017: 3 publications 2018: 5 publications 2019: 5 publications 2020: 4 publications 2021: 4 publications 2022: 0 publications 2023: 1 publication 2024: 1 publication
1973 2024

118 publications in total across all disciplines

View publications per year as a table
Jeffrey L. Lennox: publications per year, 1973 to 2024
Year Publications
1973 1
1974 0
1975 0
1976 0
1977 0
1978 0
1979 0
1980 0
1981 0
1982 0
1983 0
1984 0
1985 0
1986 0
1987 1
1988 0
1989 1
1990 0
1991 1
1992 0
1993 0
1994 0
1995 0
1996 1
1997 0
1998 3
1999 0
2000 4
2001 5
2002 5
2003 6
2004 1
2005 4
2006 2
2007 4
2008 10
2009 5
2010 6
2011 5
2012 8
2013 4
2014 10
2015 4
2016 4
2017 3
2018 5
2019 5
2020 4
2021 4
2022 0
2023 1
2024 1
Total 118
Download as CSV

Jeffrey L. Lennox publication distribution in Microbiology in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Microbiology in 2026. The highlighted bar marks where Jeffrey L. Lennox sits on this spectrum.

No. of scientists
50 100 150 200 250
Bar chart with 64 bars. Horizontal axis: publications, 55–64 to 679+. Vertical axis: number of scientists, 0 to 288. Most scientists, 288, have 135–144 publications. The last bar groups every scientist with 679 publications or more. The highlighted bar, 105–114 publications, is where this scientist sits. 55–64 publications: 8 scientists 65–74 publications: 29 scientists 75–84 publications: 55 scientists 85–94 publications: 112 scientists 95–104 publications: 137 scientists 105–114 publications: 190 scientists 115–124 publications: 235 scientists 125–134 publications: 234 scientists 135–144 publications: 288 scientists 145–154 publications: 265 scientists 155–164 publications: 264 scientists 165–174 publications: 253 scientists 175–184 publications: 276 scientists 185–194 publications: 190 scientists 195–204 publications: 234 scientists 205–214 publications: 208 scientists 215–224 publications: 198 scientists 225–234 publications: 155 scientists 235–244 publications: 161 scientists 245–254 publications: 160 scientists 255–264 publications: 146 scientists 265–274 publications: 139 scientists 275–284 publications: 148 scientists 285–294 publications: 115 scientists 295–304 publications: 96 scientists 305–314 publications: 88 scientists 315–324 publications: 106 scientists 325–334 publications: 65 scientists 335–344 publications: 76 scientists 345–354 publications: 64 scientists 355–364 publications: 62 scientists 365–374 publications: 65 scientists 375–384 publications: 61 scientists 385–394 publications: 34 scientists 395–404 publications: 44 scientists 405–414 publications: 36 scientists 415–424 publications: 35 scientists 425–434 publications: 29 scientists 435–444 publications: 33 scientists 445–454 publications: 34 scientists 455–464 publications: 25 scientists 465–474 publications: 26 scientists 475–484 publications: 20 scientists 485–494 publications: 19 scientists 495–504 publications: 16 scientists 505–514 publications: 17 scientists 515–524 publications: 23 scientists 525–534 publications: 14 scientists 535–544 publications: 14 scientists 545–554 publications: 18 scientists 555–564 publications: 12 scientists 565–574 publications: 7 scientists 575–584 publications: 9 scientists 585–594 publications: 9 scientists 595–604 publications: 9 scientists 605–614 publications: 7 scientists 615–624 publications: 9 scientists 625–634 publications: 7 scientists 635–644 publications: 4 scientists 645–654 publications: 5 scientists 655–664 publications: 6 scientists 665–674 publications: 7 scientists 675–678 publications: 3 scientists 679+ publications: 99 scientists
55–64 publications 679+

This scientist: 111 publications — 8th percentile

8% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 679 publications or more.

View publications distribution as a table
Number of Microbiology scientists by publication count, Research.com 2026 ranking edition. Based on 5,513 ranked scientists.
Publications Scientists This scientist
55–64 8
65–74 29
75–84 55
85–94 112
95–104 137
105–114 190 111
115–124 235
125–134 234
135–144 288
145–154 265
155–164 264
165–174 253
175–184 276
185–194 190
195–204 234
205–214 208
215–224 198
225–234 155
235–244 161
245–254 160
255–264 146
265–274 139
275–284 148
285–294 115
295–304 96
305–314 88
315–324 106
325–334 65
335–344 76
345–354 64
355–364 62
365–374 65
375–384 61
385–394 34
395–404 44
405–414 36
415–424 35
425–434 29
435–444 33
445–454 34
455–464 25
465–474 26
475–484 20
485–494 19
495–504 16
505–514 17
515–524 23
525–534 14
535–544 14
545–554 18
555–564 12
565–574 7
575–584 9
585–594 9
595–604 9
605–614 7
615–624 9
625–634 7
635–644 4
645–654 5
655–664 6
665–674 7
675–678 3
679+ 99
Download as CSV

Jeffrey L. Lennox D-index placement in Microbiology in 2026

The chart shows the D-index (discipline H-index) distribution of Microbiology scientists ranked by Research.com in 2026. The highlighted bar marks where Jeffrey L. Lennox sits on this spectrum.

No. of scientists
50 100 150
Bar chart with 88 bars. Horizontal axis: D-Index, 40 to 127+. Vertical axis: number of scientists, 0 to 162. Most scientists, 162, have 58 D-Index. The last bar groups every scientist with 127 D-Index or more. The highlighted bar, 44 D-Index, is where this scientist sits. 40 D-Index: 30 scientists 41 D-Index: 86 scientists 42 D-Index: 90 scientists 43 D-Index: 117 scientists 44 D-Index: 122 scientists 45 D-Index: 123 scientists 46 D-Index: 108 scientists 47 D-Index: 110 scientists 48 D-Index: 106 scientists 49 D-Index: 109 scientists 50 D-Index: 129 scientists 51 D-Index: 111 scientists 52 D-Index: 116 scientists 53 D-Index: 127 scientists 54 D-Index: 134 scientists 55 D-Index: 134 scientists 56 D-Index: 112 scientists 57 D-Index: 136 scientists 58 D-Index: 162 scientists 59 D-Index: 151 scientists 60 D-Index: 139 scientists 61 D-Index: 123 scientists 62 D-Index: 126 scientists 63 D-Index: 144 scientists 64 D-Index: 109 scientists 65 D-Index: 103 scientists 66 D-Index: 124 scientists 67 D-Index: 112 scientists 68 D-Index: 103 scientists 69 D-Index: 131 scientists 70 D-Index: 94 scientists 71 D-Index: 93 scientists 72 D-Index: 96 scientists 73 D-Index: 92 scientists 74 D-Index: 80 scientists 75 D-Index: 66 scientists 76 D-Index: 87 scientists 77 D-Index: 60 scientists 78 D-Index: 73 scientists 79 D-Index: 59 scientists 80 D-Index: 57 scientists 81 D-Index: 55 scientists 82 D-Index: 47 scientists 83 D-Index: 77 scientists 84 D-Index: 50 scientists 85 D-Index: 45 scientists 86 D-Index: 42 scientists 87 D-Index: 41 scientists 88 D-Index: 32 scientists 89 D-Index: 38 scientists 90 D-Index: 35 scientists 91 D-Index: 34 scientists 92 D-Index: 27 scientists 93 D-Index: 26 scientists 94 D-Index: 33 scientists 95 D-Index: 22 scientists 96 D-Index: 37 scientists 97 D-Index: 22 scientists 98 D-Index: 21 scientists 99 D-Index: 22 scientists 100 D-Index: 30 scientists 101 D-Index: 16 scientists 102 D-Index: 20 scientists 103 D-Index: 17 scientists 104 D-Index: 19 scientists 105 D-Index: 16 scientists 106 D-Index: 19 scientists 107 D-Index: 18 scientists 108 D-Index: 14 scientists 109 D-Index: 10 scientists 110 D-Index: 9 scientists 111 D-Index: 7 scientists 112 D-Index: 11 scientists 113 D-Index: 6 scientists 114 D-Index: 15 scientists 115 D-Index: 10 scientists 116 D-Index: 12 scientists 117 D-Index: 7 scientists 118 D-Index: 10 scientists 119 D-Index: 10 scientists 120 D-Index: 11 scientists 121 D-Index: 2 scientists 122 D-Index: 7 scientists 123 D-Index: 12 scientists 124 D-Index: 5 scientists 125 D-Index: 9 scientists 126 D-Index: 6 scientists 127+ D-Index: 95 scientists
40 D-Index 127+

This scientist: 44 D-Index — 8th percentile

8% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 127 D-Index or more.

View D-Index distribution as a table
Number of Microbiology scientists by D-index, Research.com 2026 ranking edition. Based on 5,513 ranked scientists.
D-Index Scientists This scientist
40 30
41 86
42 90
43 117
44 122 44
45 123
46 108
47 110
48 106
49 109
50 129
51 111
52 116
53 127
54 134
55 134
56 112
57 136
58 162
59 151
60 139
61 123
62 126
63 144
64 109
65 103
66 124
67 112
68 103
69 131
70 94
71 93
72 96
73 92
74 80
75 66
76 87
77 60
78 73
79 59
80 57
81 55
82 47
83 77
84 50
85 45
86 42
87 41
88 32
89 38
90 35
91 34
92 27
93 26
94 33
95 22
96 37
97 22
98 21
99 22
100 30
101 16
102 20
103 17
104 19
105 16
106 19
107 18
108 14
109 10
110 9
111 7
112 11
113 6
114 15
115 10
116 12
117 7
118 10
119 10
120 11
121 2
122 7
123 12
124 5
125 9
126 6
127+ 95
Download as CSV

Overview

Jeffrey L. Lennox is affiliated with Emory University in the United States and specializes in multiple areas within medicine, particularly focusing on infectious diseases, epidemiology, virology, neurology, and genetics. Their research primarily addresses topics related to HIV/AIDS drug development and treatment, HIV research and treatment, COVID-19 clinical research studies, pharmacological effects and toxicity studies, long-term effects of COVID-19, sepsis diagnosis and treatment, and genetic associations and epidemiology.

Their recent publications cover notable studies in both infectious diseases and immunology, including:

  • Lenzilumab in hospitalised patients with COVID-19 pneumonia (LIVE-AIR): a phase 3, randomised, placebo-controlled trial, 2021, The Lancet Respiratory Medicine
  • National Institutes of Health COVID-19 Treatment Guidelines Panel: Perspectives and Lessons Learned, 2024, Annals of Internal Medicine
  • Tissue specificity-aware TWAS (TSA-TWAS) framework identifies novel associations with metabolic, immunologic, and virologic traits in HIV-positive adults, 2021, PLoS Genetics
  • "Cure" Versus "Clinical Remission": The Impact of a Medication Description on the Willingness of People Living with HIV to Take a Medication, 2020, AIDS and Behavior
  • Distinct cellular immune properties in cerebrospinal fluid are associated with cognition in HIV-infected individuals initiating antiretroviral therapy, 2020, Journal of Neuroimmunology

The scientist frequently collaborates with several co-authors, including:

  • Roy M. Gulick
  • Eric S. Daar
  • Jason Baker
  • Jing Zhao
  • Daria J. Hazuda

Jeffrey L. Lennox's work appears in multiple prominent venues with repeated contributions to UNC Libraries, as well as publications in The Lancet Respiratory Medicine, Annals of Internal Medicine, PLoS Genetics, and AIDS and Behavior.

Their research contributions are situated mainly within the medical field, with a strong focus on infectious diseases and related subfields. The range of topics covered demonstrates a focus on both clinical and genetic aspects of infectious diseases, with considerable attention to HIV/AIDS and COVID-19.

Best Publications

  • Raltegravir with Optimized Background Therapy for Resistant HIV-1 Infection

    Roy T. Steigbigel;David A. Cooper;Princy N. Kumar;Joseph E. Eron

  • Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naive patients with HIV-1 infection: a multicentre, double-blind randomised controlled trial

    Jeffrey L. Lennox;Edwin DeJesus;Adriano Lazzarin;Richard B. Pollard

  • Guidelines for the Management of Chronic Kidney Disease in HIV-Infected Patients: Recommendations of the HIV Medicine Association of the Infectious Diseases Society of America

    Samir K. Gupta;Joseph A. Eustace;Jonathan A. Winston;Ivy I. Boydstun

  • Subgroup and resistance analyses of raltegravir for resistant HIV-1 infection.

    David A. Cooper;Roy T. Steigbigel;Jose M. Gatell;Jurgen K. Rockstroh

  • Efficacy and Tolerability of 3 Nonnucleoside Reverse Transcriptase Inhibitor–Sparing Antiretroviral Regimens for Treatment-Naive Volunteers Infected With HIV-1: A Randomized, Controlled Equivalence Trial

    Jeffrey L. Lennox;Raphael J. Landovitz;Heather J. Ribaudo;Ighovwerha Ofotokun

  • Durable efficacy and safety of raltegravir versus efavirenz when combined with tenofovir/emtricitabine in treatment-naive HIV-1-infected patients: final 5-year results from STARTMRK.

    Jürgen K Rockstroh;Edwin DeJesus;Jeffrey L Lennox;Yazdan Yazdanpanah

  • Long-term efficacy and safety of Raltegravir combined with optimized background therapy in treatment-experienced patients with drug-resistant HIV infection: week 96 results of the BENCHMRK 1 and 2 Phase III trials

    Roy T. Steigbigel;David A. Cooper;Hedy Teppler;Joseph J. Eron

  • Clinical Practice Guideline for the Management of Chronic Kidney Disease in Patients Infected With HIV: 2014 Update by the HIV Medicine Association of the Infectious Diseases Society of America

    Gregory M. Lucas;Michael J. Ross;Peter G. Stock;Michael G. Shlipak

  • Raltegravir Versus Efavirenz Regimens in Treatment-Naive HIV-1-Infected Patients: 96-Week Efficacy, Durability, Subgroup, Safety, and Metabolic Analyses

    Jeffrey L. Lennox;Edwin DeJesus;Daniel S. Berger;Adriano Lazzarin

  • A dangerous dilemma: management of infectious intracranial aneurysms complicating endocarditis

    Philip J Peters;Taylor Harrison;Jeffrey L Lennox

  • Correlation of Human Immunodeficiency Virus Type 1 RNA Levels in Blood and the Female Genital Tract

    Clyde E. Hart;Jeffrey L. Lennox;Melody Pratt-Palmore;Thomas C. Wright

  • HIV in body fluids during primary HIV infection: implications for pathogenesis, treatment and public health.

    Christopher D. Pilcher;Diane C. Shugars;Susan A. Fiscus;William C. Miller

  • Long-term Treatment With Raltegravir or Efavirenz Combined With Tenofovir/Emtricitabine for Treatment-Naive Human Immunodeficiency Virus-1–Infected Patients: 156-Week Results From STARTMRK

    Jürgen K. Rockstroh;Jeffrey L. Lennox;Edwin Dejesus;Michael S. Saag

  • Randomized trial of the quantitative and functional antibody responses to a 7-valent pneumococcal conjugate vaccine and/or 23-valent polysaccharide vaccine among HIV-infected adults.

    Daniel R. Feikin;Cheryl M. Elie;Matthew B. Goetz;Jeffrey L. Lennox

  • Human Immunodeficiency Virus Type 1 Controllers but Not Noncontrollers Maintain CD4 T Cells Coexpressing Three Cytokines

    Sunil Kannanganat;Bill G. Kapogiannis;Bill G. Kapogiannis;Chris Ibegbu;Lakshmi Chennareddi

  • Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2B6 and Efavirenz-Containing Antiretroviral Therapy.

    Zeruesenay Desta;Roseann S. Gammal;Roseann S. Gammal;Li Gong;Michelle Whirl-Carrillo

  • Healthy HIV-1-Infected Individuals on Highly Active Antiretroviral Therapy Harbor HIV-1 in Their Alveolar Macrophages

    Sushma K. Cribbs;Jeffrey Lennox;Angela M. Caliendo;Lou Ann Brown

  • Efficacy and safety of raltegravir for treatment of HIV for 5 years in the BENCHMRK studies: final results of two randomised, placebo-controlled trials

    Joseph J. Eron;David A. Cooper;Roy T. Steigbigel;Bonaventura Clotet

  • Ineffective platelet production in thrombocytopenic human immunodeficiency virus-infected patients

    James L. Cole;Ulla M. Marzec;Clifford J. Gunthel;Simon Karpatkin

  • Impaired Hepatitis C Virus (HCV)-Specific Effector CD8+ T Cells Undergo Massive Apoptosis in the Peripheral Blood during Acute HCV Infection and in the Liver during the Chronic Phase of Infection

    Henry Radziewicz;Chris C. Ibegbu;Huiming Hon;Melissa K. Osborn

  • Dysregulated B cell expression of RANKL and OPG correlates with loss of bone mineral density in HIV infection.

    Kehmia Titanji;Aswani Vunnava;Anandi N. Sheth;Cecile Delille

  • Infrequent Diagnosis of Primary Human Immunodeficiency Virus Infection: Missed Opportunities in Acute Care Settings

    Amy C. Weintrob;Julieta Giner;Prema Menezes;Ericka Patrick

  • Disseminated Mycobacterium avium complex disease among patients infected with human immunodeficiency virus, 1985-2000.

    C. Robert Horsburgh;Jill Gettings;Lorraine N. Alexander;Jeffrey L. Lennox

Frequent Co-Authors

David W. Haas
David W. Haas Vanderbilt University Medical Center
Kirk A. Easley
Kirk A. Easley Emory University
Judith S. Currier
Judith S. Currier University of California, Los Angeles
Adriano Lazzarin
Adriano Lazzarin Vita-Salute San Raffaele University
Carlos del Rio
Carlos del Rio Emory University
Jürgen K. Rockstroh
Jürgen K. Rockstroh University Hospital Bonn
M. Neale Weitzmann
M. Neale Weitzmann Emory University
Randi Y. Leavitt
Randi Y. Leavitt MSD (United States)
Thomas C. Wright
Thomas C. Wright Columbia University
Matthew Bidwell Goetz
Matthew Bidwell Goetz University of California, Los Angeles

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

For those interested in exploring alternative or complementary fields to Microbiology, online degrees in healthcare and health information management offer promising career opportunities. Programs recognized as the best online health information management degree cahiim accredited ensure quality education that meets industry standards, preparing graduates for roles in managing patient data and healthcare systems.

If you're looking to quickly enter the healthcare administration sector, accelerated options like medical billing and coding certificate online accelerated programs can provide certification in a matter of months, opening doors to essential, high-demand positions.

Moreover, for those aiming higher in the healthcare field, understanding online healthcare degrees that pay well can guide decision-making toward degrees that yield strong financial returns and stable job prospects.

Finally, public health is a growing sector where many microbiology graduates find meaningful roles. The availability of easy admission online mph programs allows motivated individuals to continue their education without the hassle of stringent entry requirements, making it an accessible path to advance your career in managing health on a larger scale.

Best Scientists Citing Jeffrey L. Lennox

Trending Scientists

Recently Published Articles